Gene · 6121
Papers3,325
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 3,325
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| AAV-Based Strategies for Treatment of Retinal and Choroidal Vascular Diseases: Advances in Age-Related Macular Degeneration and Diabetic Retinopathy Therapies. | BioDrugs | 2024 | 37878215 | PubTator, text mining | PubMed |
| Multi-luminance mobility testing after gene therapy in the context of retinal functional diagnostics. | Graefes Arch Clin Exp Ophthalmol | 2024 | 37768368 | PubTator, text mining | PubMed |
| A Novel Primary Porcine Retinal Pigment Epithelium Cell Model with Preserved Properties. | Curr Eye Res | 2024 | 37725007 | PubTator, text mining | PubMed |
| A morphometric analysis of the retinal arterioles with adaptive optics imaging in RPE65-associated retinal dystrophy after treatment with voretigene neparvovec. | Acta Ophthalmol | 2024 | 37715554 | PubTator, text mining | PubMed |
| Single Center Experience with Voretigene Neparvovec Gene Augmentation Therapy in RPE65 Mutation-Associated Inherited Retinal Degeneration in a Clinical Setting. | Ophthalmology | 2024 | 37704110 | PubTator, text mining | PubMed |
| Classification and Growth Rate of Chorioretinal Atrophy after Voretigene Neparvovec-Rzyl for RPE65-Mediated Retinal Degeneration. | Ophthalmol Retina | 2024 | 37660736 | PubTator, text mining | PubMed |
| Advances in the engineering of the outer blood-retina barrier: From in-vitro modelling to cellular therapy. | Bioact Mater | 2024 | 37637086 | PubTator, text mining | PubMed |
| The Extraordinary Phenotypic and Genetic Variability of Retinal and Macular Degenerations: The Relevance to Therapeutic Developments. | Cold Spring Harb Perspect Med | 2024 | 37604589 | PubTator, text mining | PubMed |
| Clinical applications of the CRISPR/Cas9 genome-editing system: Delivery options and challenges in precision medicine. | Genes Dis | 2024 | 37588217 | PubTator, text mining | PubMed |
| Full-field stimulus threshold testing: a scoping review of current practice. | Eye (Lond) | 2024 | 37443335 | PubTator, text mining | PubMed |
| Unlocking therapeutic potential: dual gene therapy for ameliorating the disease phenotypes in a mouse model of RPE65 Leber congenital amaurosis. | Front Med (Lausanne) | 2023 | 38264046 | PubTator, text mining | PubMed |
| Subconfluent ARPE-19 Cells Display Mesenchymal Cell-State Characteristics and Behave like Fibroblasts, Rather Than Epithelial Cells, in Experimental HCMV Infection Studies. | Viruses | 2023 | 38257749 | PubTator, text mining | PubMed |
| The Potential and Application of iPSCs in Gene and Cell Therapy for Retinopathies and Optic Neuropathies. | Acta Naturae | 2023 | 38234607 | PubTator, text mining | PubMed |
| Scavenging of Cation Radicals of the Visual Cycle Retinoids by Lutein, Zeaxanthin, Taurine, and Melanin. | Int J Mol Sci | 2023 | 38203675 | PubTator, text mining | PubMed |
| Key Factors in the Complex and Coordinated Network of Skin Keratinization: Their Significance and Involvement in Common Skin Conditions. | Int J Mol Sci | 2023 | 38203406 | PubTator, text mining | PubMed |
| RNA-Seq Analysis of Trans-Differentiated ARPE-19 Cells Transduced by AAV9-AIPL1 Vectors. | Int J Mol Sci | 2023 | 38203368 | PubTator, text mining | PubMed |
| AAV for Gene Therapy in Ocular Diseases: Progress and Prospects. | Research (Wash D C) | 2023 | 38188726 | PubTator, text mining | PubMed |
| Whole genome sequencing and comparative genomics of Mycobacterium orygis isolated from different animal hosts to identify specific diagnostic markers. | Front Cell Infect Microbiol | 2023 | 38188626 | PubTator, text mining | PubMed |
| Progress and challenges of plant-derived nucleic acids as therapeutics in macrophage-mediated RNA therapy. | Front Immunol | 2023 | 38155963 | PubTator, text mining | PubMed |
| Retinitis pigmentosa GTPase regulator-related retinopathy and gene therapy. | Saudi J Ophthalmol | 2023 | 38155670 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6121/papers?page=11